Then we found that SCD participants, especially the SCD participants with obvious Aβ-related pathologic changes, had lower methylation levels of BIN1 promoter compared with controls, which indicated that hypomethylation of BIN1 promoter might increase the risk of preclinical AD. Here, BIN1 is linked to Alzheimer disease.